ABI-009 (nab-sirolimus) Pipeline Clinical Studies
- Aadi’s phase 2 registrational trial for ABI-009 (nab-sirolimus) in patients with advanced PEComa (Perivascular Epithelioid Cell tumors) has been completed.
- ABI-009 (nab-sirolimus) has received FDA and EMA Orphan Designation for PEComa as well as FDA Fast Track and Breakthrough Therapy Designations for advanced (metastatic or locally advanced) malignant PEComa.
- Aadi is also a recipient of FDA’s Orphan Product Development Grant for this indication.